The Use of Enoxaparin and Insuflon™ Catheter to Direct Treatment of CVL Thrombosis

Neonates are surviving at younger gestational ages and with more significant congenital anomalies. In addition, the clinical interventions required to care for them are also becoming more complex and technical, which, in turn, increases the risk of complications related to these interventions. Included in these risks is the potential for central venous line (CVL)-associated thrombus or, for the purposes of this paper, venous thromboembolism (VTE). Though the true incidence of VTE is not known, CVLs remain the most common cause of VTE in the neonate. Treatment consists of low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) followed by LMWH for a period of 6 weeks to 3 months. The Insuflon™ Subcutaneous Catheter is a safe and effective option for anticoagulation administration for those infants diagnosed with VTEs.